Literature DB >> 7777526

Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis.

A Almasan1, Y Yin, R E Kelly, E Y Lee, A Bradley, W Li, J R Bertino, G M Wahl.   

Abstract

The retinoblastoma susceptibility gene (Rb) participates in controlling the G1/S-phase transition, presumably by binding and inactivating E2F transcription activator family members. Mouse embryonic fibroblasts (MEFs) with no, one, or two inactivated Rb genes were used to determine the specific contributions of Rb protein to cell cycle progression and gene expression. MEFs lacking both Rb alleles (Rb-/-) entered S phase in the presence of the dihydrofolate reductase inhibitor methotrexate. Two E2F target genes, dihydrofolate reductase and thymidylate synthase, displayed elevated mRNA and protein levels in Rb- MEFs. Since absence of functional Rb protein in MEFs is sufficient for S-phase entry under growth-limiting conditions, these data indicate that the E2F complexes containing Rb protein, and not the Rb-related proteins p107 and p130, may be rate limiting for the G1/S transition. Antineoplastic drugs caused accumulation of p53 in the nuclei of both Rb+/+ and Rb-/- MEFs. While p53 induction led to apoptosis in Rb-/- MEFs, Rb+/- and Rb+/+ MEFs underwent cell cycle arrest without apoptosis. These results reveal that diverse growth signals work through Rb to regulate entry into S phase, and they indicate that absence of Rb protein produces a constitutive DNA replication signal capable of activating a p53-associated apoptotic response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777526      PMCID: PMC41709          DOI: 10.1073/pnas.92.12.5436

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Isolation and characterization of a variant dihydrofolate reductase cDNA from methotrexate-resistant murine L5178Y cells.

Authors:  R S McIvor; C C Simonsen
Journal:  Nucleic Acids Res       Date:  1990-12-11       Impact factor: 16.971

2.  The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle.

Authors:  D W Goodrich; N P Wang; Y W Qian; E Y Lee; W H Lee
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

3.  36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO.

Authors:  J Laborda
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

4.  Transcription factor E2F is required for efficient expression of the hamster dihydrofolate reductase gene in vitro and in vivo.

Authors:  M C Blake; J C Azizkhan
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

5.  Structure of the gene for mouse thymidylate synthase. Locations of introns and multiple transcriptional start sites.

Authors:  T L Deng; D W Li; C H Jenh; L F Johnson
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

6.  Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation.

Authors:  A H Wyllie
Journal:  Nature       Date:  1980-04-10       Impact factor: 49.962

7.  Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation.

Authors:  P L Chen; P Scully; J Y Shew; J Y Wang; W H Lee
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

8.  p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein.

Authors:  R J Slebos; M H Lee; B S Plunkett; T D Kessis; B O Williams; T Jacks; L Hedrick; M B Kastan; K R Cho
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

9.  Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.

Authors:  B T Lin; S Gruenwald; A O Morla; W H Lee; J Y Wang
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

10.  The retinoblastoma protein is phosphorylated on multiple sites by human cdc2.

Authors:  J A Lees; K J Buchkovich; D R Marshak; C W Anderson; E Harlow
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  87 in total

Review 1.  Death and destruction of activated T lymphocytes.

Authors:  I N Crispe
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  J domain-independent regulation of the Rb family by polyomavirus large T antigen.

Authors:  Q Sheng; T M Love; B Schaffhausen
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  The kinetic origins of the restriction point in the mammalian cell cycle.

Authors:  B D Aguda; Y Tang
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

4.  Gene expression changes in response to E2F1 activation.

Authors:  Jens Stanelle; Thorsten Stiewe; Carmen C Theseling; Martin Peter; Brigitte M Pützer
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

Review 5.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

6.  Is caspase-8 a neuroendocrine lung tumor suppressor?

Authors:  Suparna Mazumder; Alexandru Almasan
Journal:  Cancer Biol Ther       Date:  2002 Jan-Feb       Impact factor: 4.742

7.  Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system.

Authors:  D MacPherson; J Sage; D Crowley; A Trumpp; R T Bronson; T Jacks
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

8.  Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.

Authors:  W Li; J Fan; D Hochhauser; D Banerjee; Z Zielinski; A Almasan; Y Yin; R Kelly; G M Wahl; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

9.  Id2 promotes apoptosis by a novel mechanism independent of dimerization to basic helix-loop-helix factors.

Authors:  M Florio; M C Hernandez; H Yang; H K Shu; J L Cleveland; M A Israel
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

Review 10.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.